MOYOM Biotech has completed a new financing round from the Cathay Consumer Co-Creation Fund to accelerate international growth of its regenerative aesthetics business. Financial terms of the financing were not disclosed.
The Cathay Consumer Co-Creation Fund is managed by Cathay Capital and was jointly established by Cathay Capital, L’Oréal and the Shanghai Jing’an District Government.
The fund is focused on innovation spanning beauty, health and skin science.
Founded in 2018, MOYOM develops nanomedical biomaterials and Class III absorbable implantable medical devices, with a particular focus on calcium hydroxylapatite regenerative materials.
Its flagship brand is Aphranel, a CaHA-based regenerative aesthetics product designed to provide immediate structural support, regenerative stimulation and complete biodegradation.
MOYOM’s underlying platform includes its proprietary ACD-MT raspberry-shaped through-hole CaHA microspheres and PCD-ETT physically cross-linked CMC gel technology.
The company said those technologies are designed to combine structural performance, regenerative interaction and controlled biodegradation.
Aphranel received Class III medical device registration from China’s National Medical Products Administration in February 2025.
The product subsequently received certification under the European Union Medical Device Regulation in May 2026.
Since its commercial launch in May 2025, Aphranel has been introduced at more than 700 medical aesthetics clinics across China.
MOYOM plans to use Cathay Capital’s investment and global network to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets.
The company also plans to continue investing in next-generation regenerative biomaterials.
